Phase II ZUMA-1: Interim Analysis of Anti-CD19 CAR T-Cell Therapy in Patients With Refractory Aggressive DLBCL

December 3-6, 2016; San Diego, California
Interim analysis reported significantly higher ORR and markedly greater CR with KTE-C19 vs historical rates in chemorefractory patients with DLBCL.
Format: Microsoft PowerPoint (.ppt)
File Size: 602 KB
Released: December 9, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Celgene Corporation
Incyte
Merck & Co., Inc.
Seattle Genetics

Related Content

Read expert answers to clinician questions on optimizing the care of patients with CLL in today’s practice, from Clinical Care Options (CCO)

Ian W. Flinn, MD, PhD Susan M. O'Brien, MD John Pagel Headshot John Pagel, MD, PhD Released: January 15, 2021

Expert answers to clinician questions on current challenges in managing patients with myelodysplastic syndromes (MDS), from Clinical Care Options (CCO)

Guillermo Garcia-Manero, MD Rami S. Komrokji, MD Jamile Shammo, MD, FASCP, FACP Released: January 11, 2021

Brief expert slideset from Clinical Care Options (CCO) on how and when to test for NTRK fusions in patients with head and neck cancer

Aarti Bhatia, MD, MPH Released: January 5, 2021

Brief expert slideset from Clinical Care Options (CCO) reviews current clinical trials of immunotherapies for patients with head and neck cancer

Barbara Burtness, MD Released: January 5, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue